SCHEMBL23217026

SCHEMBL23217026

COc1ccc(Cl)c(Cl)c1[C@@H]1CCN(C(=O)OC(C)(C)C)[C@H](C(=O)O)C1

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HTR2A P28223 3/20 0.40
HTR2C P28335 3/20 0.40
HTR2B P41595 3/20 0.40
PDE4B Q07343 4/20 0.40
ALDH1A1 P00352 2/20 0.39
HSD17B10 Q99714 2/20 0.37
MEN1 O00255 4/20 0.37
KMT2A Q03164 4/20 0.37
GRM5 P41594 1/20 0.37
OPRK1 P41145 1/20 0.37
NPC1 O15118 1/20 0.36
MAPK1 P28482 1/20 0.36
GPR35 Q9HC97 1/20 0.36
GPR55 Q9Y2T6 1/20 0.36
STS P08842 1/20 0.36
MAPT P10636 1/20 0.35
NPSR1 Q6W5P4 2/20 0.35
LMNA P02545 1/20 0.35
PDE4A P27815 2/20 0.35
PDE4C Q08493 2/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23215050 1.00 HTR2A (0.40) HTR2AHTR2CHTR2BPDE4BALDH1A1
SCHEMBL29768438 1.00 HTR2A (0.40) HTR2AHTR2CHTR2BPDE4BALDH1A1
SCHEMBL29845000 1.00 HTR2A (0.40) HTR2AHTR2CHTR2BPDE4BALDH1A1
SCHEMBL29845062 0.92 HTR2A (0.40) HTR2AHTR2CHTR2BPDE4BALDH1A1
SCHEMBL23227501 0.92 HTR2A (0.40) HTR2AHTR2CHTR2BPDE4BALDH1A1
SCHEMBL23217253 0.92 HTR2A (0.42) HTR2AHTR2CHTR2BPDE4BALDH1A1
SCHEMBL29845173 0.92 HTR2A (0.42) HTR2AHTR2CHTR2BPDE4BALDH1A1
SCHEMBL23217489 0.92 HTR2A (0.42) HTR2AHTR2CHTR2BPDE4BALDH1A1
SCHEMBL29844882 0.92 HTR2A (0.42) HTR2AHTR2CHTR2BPDE4BALDH1A1
SCHEMBL23227506 0.91 ALDH1A1 (0.40) HTR2AHTR2CHTR2BPDE4BALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230049231-A1 ARYL HETEROBICYCLIC COMPOUNDS AS Kv1.3 POTASSIUM SHAKER CHANNEL BLOCKERS D. E. SHAW RESEARCH, LLC 2023-02-16 US disclosed
US-20230049231-A1 ARYL HETEROBICYCLIC COMPOUNDS AS Kv1.3 POTASSIUM SHAKER CHANNEL BLOCKERS D. E. SHAW RESEARCH, LLC 2023-02-16 US disclosed
EP-4041405-A1 ARYL HETEROBICYCLIC COMPOUNDS AS KV1.3 POTASSIUM SHAKER CHANNEL BLOCKERS D.E. Shaw Research, LLC (US) 2022-08-17 EP disclosed
CN-114828963-A Arylheterobicyclic compounds as Kv1.3 potassium SHAKER channel blockers D·E·萧尔研究有限责任公司 2022-07-29 CN disclosed
WO-2021071832-A1 ARYL HETEROBICYCLIC COMPOUNDS AS KV1.3 POTASSIUM SHAKER CHANNEL BLOCKERS D.E. SHAW RESEARCH, LLC (US) 2021-04-15 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230049231-A1 ARYL HETEROBICYCLIC COMPOUNDS AS Kv1.3 POTASSIUM SHAKER CHANNEL BLOCKERS KCNB1, KCNJ2, KCNB2 HTR2A 1799/4885HTR2C 1162/4885HTR2B 464/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.